The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population

Journal of Stroke and Cerebrovascular Diseases

Volumn 26, Issue 1, 2017, Pages 64-69

  Bernaitis, Nijole ^a   Ching, Chi Keong ^b   Chen, Liping ^b   Hon, Jin Shing ^b   Teo, Siew Chong ^b   Davey, Andrew K ^a   Anoopkumar Dukie, Shailendra ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

anticoagulant; atrial fibrillation; predictor model; Warfarin

Indexed keywords

AMIODARONE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CHINESE; DRUG CONTROL; FEMALE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALAY (PEOPLE); MALE; MEDICAL HISTORY; POPULATION RISK; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX AGE MEDICAL HISTORY TREATMENT TOBACCO USE RACE SCORE; SINGAPOREAN; AGE; ANCESTRY GROUP; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SINGAPORE; STROKE; TOBACCO USE;

AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SINGAPORE; STROKE; TOBACCO USE; WARFARIN;

EID: 84995752721     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.030     Document Type: Article

References (27)

1. 1 Putnam, A., Gu, X., Haymart, B., et al. The changing characteristics of atrial fibrillation patients treated with warfarin. J Thromb Thrombolysis 40 (2015), 488–493.
2. 2 Bauer, K.A., Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013 (2013), 464–470.
3. 3 Chan, N.C., Paikin, J.S., Hirsch, J., et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 111 (2014), 798–807.
4. 4 Gomez-Outes, A., Terleira-Fernandez, A.I., Calvo-Rojas, G., et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis, 2013, 2013, 18.
5. 5 Shah, S.V., Gage, B.F., Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123 (2011), 2562–2570.
6. 6 Navgren, M., Forsblad, J., Wieloch, M., Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. J Thromb Thrombolysis 38 (2014), 98–104.
7. 7 White, H.D., Gruber, M., Feyzi, J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167 (2007), 239–245.
8. 8 Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33 (2012), 2719–2747.
9. 9 Morgan, C.L., McEwan, P., Tukiendorf, A., et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 124 (2009), 37–41.
10. 10 Wallentin, L., Lopes, R.D., Hanna, M., et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation 127 (2013), 2166–2176.
11. 11 Apostolakis, S., Sullivan, R.M., Olshansky, B., et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 144 (2013), 1555–1563.
12. 2 score predicts poor anticoagulation control in AF patients: a prospective ‘real-world’ inception cohort study. Am J Med 128 (2015), 1237–1243.
13. 13 Poli, D., Antonucci, E., Testa, S., et al. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 9 (2014), 443–447.
14. 14 Gallego, P., Roldán, V., Marin, F., et al. SAMe-TT 2 R 2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 127 (2014), 1083–1088.
15. 15 Chan, P.H., Hai, J.J., Chan, E.W., et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS ONE, 11, 2016 e0150674.
16. 16 Rosendaal, F., Cannegieter, S., Van der Meer, F., et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69 (1993), 236–239.
17. 17 Proietti, M., Lip, G.Y., Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 1 (2015), 150–152.
18. 18 Dang, M.-T.N., Hambleton, J., Kayser, S.R., The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39 (2005), 1008–1012.
19. 19 Lee, S.C., Ng, S.S., Oldenburg, J., et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79 (2006), 197–205.
20. 20 Yap, L.B., Eng, D.T.S., Sivalingam, L., et al. A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb Hemost, 2015, 10.1177/1076029615584664 pii: 1076029615584664.
21. 21 Lip, G.Y., Wang, K.-L., Chiang, C.-E., Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 180 (2015), 246–254.
22. 22 Chiang, C.-E., Wang, K.-L., Lip, G., Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 111 (2014), 789–797.
23. 23 Bhusri, S., Ansell, J., New anticoagulants in atrial fibrillation: an update for clinicians. Ther Adv Chronic Dis 3 (2012), 37–45.
24. 24 Chen, C.-H., Chen, M.-C., Gibbs, H., et al. Antithrombotic treatment for stroke prevention in atrial fibrillation: the Asian agenda. Int J Cardiol 191 (2015), 244–253.
25. 25 Wallentin, L., Yusuf, S., Ezekowitz, M.D., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376 (2010), 975–983.
26. 26 Fauchier, L., Poli, D., Olshansky, B., The SAMe-TT2R2 score and quality of anticoagulation in AF: can we predict which patient benefits from anticoagulation?. Thromb Haemost 114 (2015), 657–659.
27. 27 Singer, D.E., Hellkamp, A.S., Piccini, J.P., et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2, 2013, e000067.